TY - JOUR
T1 - Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential
T2 - Management and Fertility Preservation Options
AU - Reynolds, Anna C.
AU - McKenzie, Laurie J.
N1 - Publisher Copyright:
© American Society of Clinical Oncology.
PY - 2023/4/20
Y1 - 2023/4/20
N2 - PURPOSETo review the complex concerns of oncofertility created through increased cancer survivorship and the long-term effects of cancer treatment in young adults.DESIGNReview chemotherapy-induced ovarian dysfunction, outline how fertility may be addressed before treatment initiation, and discuss barriers to oncofertility treatment and guidelines for oncologists to provide this care to their patients.CONCLUSIONIn women of childbearing potential, ovarian dysfunction resulting from cancer therapy has profound short- and long-term implications. Ovarian dysfunction can manifest as menstrual abnormalities, hot flashes, night sweats, impaired fertility, and in the long term, increased cardiovascular risk, bone mineral density loss, and cognitive deficits. The risk of ovarian dysfunction varies between drug classes, number of received lines of therapy, chemotherapy dosage, patient age, and baseline fertility status. Currently, there is no standard clinical practice to evaluate patients for their risk of developing ovarian dysfunction with systemic therapy or means to address hormonal fluctuations during treatment. This review provides a clinical guide to obtain a baseline fertility assessment and facilitate fertility preservation discussions.
AB - PURPOSETo review the complex concerns of oncofertility created through increased cancer survivorship and the long-term effects of cancer treatment in young adults.DESIGNReview chemotherapy-induced ovarian dysfunction, outline how fertility may be addressed before treatment initiation, and discuss barriers to oncofertility treatment and guidelines for oncologists to provide this care to their patients.CONCLUSIONIn women of childbearing potential, ovarian dysfunction resulting from cancer therapy has profound short- and long-term implications. Ovarian dysfunction can manifest as menstrual abnormalities, hot flashes, night sweats, impaired fertility, and in the long term, increased cardiovascular risk, bone mineral density loss, and cognitive deficits. The risk of ovarian dysfunction varies between drug classes, number of received lines of therapy, chemotherapy dosage, patient age, and baseline fertility status. Currently, there is no standard clinical practice to evaluate patients for their risk of developing ovarian dysfunction with systemic therapy or means to address hormonal fluctuations during treatment. This review provides a clinical guide to obtain a baseline fertility assessment and facilitate fertility preservation discussions.
UR - http://www.scopus.com/inward/record.url?scp=85152635738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152635738&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.01885
DO - 10.1200/JCO.22.01885
M3 - Review article
C2 - 36888938
AN - SCOPUS:85152635738
SN - 0732-183X
VL - 41
SP - 2281
EP - 2292
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 12
ER -